Q-omics provides the consensus-scored ZRSR2P1 profile across patient tissues and cancer cell-line models. ZRSR2P1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZRSR2P1 is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, ZRSR2P1 RNA expression shows 17,291 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, BLCA, and UVM as cancer lineages where ZRSR2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZRSR2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZRSR2P1 survival associations across molecular data types. ZRSR2P1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZRSR2P1 RNA expression–survival associations across cancer types. High ZRSR2P1 expression shows unfavorable associations in KICH and UVM, but favorable associations in HNSC, MESO, KIRP and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZRSR2P1 RNA expression.
This table summarizes ZRSR2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZRSR2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZRSR2P1 shows lower tumor expression in BLCA, LUSC, THCA, UCEC and KICH and higher tumor expression in CHOL. The BLCA box plot shows higher ZRSR2P1 RNA expression in normal versus tumor tissue (log2 FC = −0.096, t-test p = .003).
This table shows molecular features associated with ZRSR2P1 in patient tissues and cancer cell lines. In patient samples, ZRSR2P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZRSR2P1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma.
